Actively Recruiting
Improving Heart Blood Flow in Women With HIV and Diabetes or Kidney Disease Through Specialist Referral and SGLT2 Inhibitors
Led by Massachusetts General Hospital · Updated on 2026-09-08
80
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Women living with HIV face a higher risk of myocardial infarction heart attack compared to women without HIV. This increased risk may be linked to a reduced ability of the hearts large and small arteries to increase blood flow when more oxygen is needed. Researchers are studying women with HIV who also have diabetes, chronic kidney disease, or both, to assess if treatment approaches can improve blood flow and reduce heart attack risk. This phase 2 study focuses on prevention and evaluates medications called sodium glucose transporter 2 SGLT2 inhibitors, which are approved for diabetes and kidney disease but are underused in people with HIV. Participants are randomly assigned to one of two groups one receives health education plus referral to see a specialist either an endocrinologist or nephrologist for possible treatment with SGLT2 inhibitors, and the other receives health education alone. The SGLT2 inhibitor therapy, if prescribed, involves medications like empagliflozin or dapagliflozin taken orally once daily. Before starting, participants undergo tests including history, physical exams, lab work, and cardiac PETCT scans to confirm reduced blood flow in the heart arteries. The study lasts six months, after which these assessments are repeated to evaluate changes. During the study, participants will be monitored through medical history review, physical examinations, laboratory tests, and advanced heart imaging scans. Researchers will measure the hearts coronary flow reserve and ectopic fat tissue around the heart, along with blood and urine markers related to kidney function, metabolism, inflammation, and HIV-specific factors. The goal is to see if SGLT2 inhibitor therapy or specialist referral alone can improve heart blood flow and related health markers. The trial runs until June 2029, with the primary outcomes assessed at 24 weeks.
CONDITIONS
Brief Title
Improving Coronary Vascular Health in Women
Research Team
S
Sarah Chu, NP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here